High-molecular-weight kininogen cleavage correlates with disease states in the bradykinin-mediated angioedema due to hereditary C1-inhibitor deficiency

Clinical and Experimental Allergy

Volumn 44, Issue 12, 2014, Pages 1503-1514

  Suffritti, C ^a   Zanichelli, A ^a   Maggioni, L ^a   Bonanni, E ^a   Cugno, M ^a   Cicardi, M ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Angioedema; Biomarkers; C1 inhibitor deficiency; Disease severity; High molecular weight kininogen; Kallikrein

Indexed keywords

BRADYKININ; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C4; HIGH MOLECULAR WEIGHT KININOGEN; STEROID;

ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; BLOOD; CASE CONTROL STUDY; CHEMOPROPHYLAXIS; CHILD; DISEASE COURSE; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; MUTATION; PROTEIN DEGRADATION; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANGIOEDEMAS, HEREDITARY; BRADYKININ; CASE-CONTROL STUDIES; CHEMOPREVENTION; CHILD; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT C1Q; COMPLEMENT C4; DISEASE PROGRESSION; FEMALE; HUMANS; KININOGEN, HIGH-MOLECULAR-WEIGHT; MALE; MIDDLE AGED; MUTATION; PROTEOLYSIS; SEVERITY OF ILLNESS INDEX; STEROIDS; YOUNG ADULT;

EID: 84911374174     PISSN: 09547894     EISSN: 13652222     Source Type: Journal    
DOI: 10.1111/cea.12293     Document Type: Article

References (61)

1. Stoppa-Lyonnet D, Tosi M, Laurent J, Sobel A, Lagrue G, Meo T. Altered C1 inhibitor genes in type I hereditary angioedema. N Engl J Med 1987; 317:1-6.
2. Cicardi M, Igarashi T, Rosen FS, Davis AE 3rd. Molecular basis for the deficiency of complement 1 inhibitor in type I hereditary angioneurotic edema. J Clin Invest 1987; 79:698-702.
3. Kalmar L, Hegedus T, Farkas H, Nagy M, Tordai A. HAE-C1-INHdb: a novel interactive, locus-specific mutation database for the C1 inhibitor gene. Hum Mutat 2004; 25:1-5.
4. Pappalardo E, Caccia S, Suffritti C, Tordai A, Zingale LC, Cicardi M. Mutation screening of C1 inhibitor gene in 108 unrelated families with hereditary angioedema: functional and structural correlates. Mol Immunol 2008; 45:3536-44.
5. Kalmar L, Bors A, Farkas H et al. Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema. Hum Mutat 2003; 22:498.
6. Roche O, Blanch A, Duponchel C, Fontan G, Tosi M, Lopez-Trascasa M. Hereditary angioedema: the mutation spectrum of SERPING1/C1NH in a large Spanish cohort. Hum Mutat 2005; 26:135-44.
7. Verpy E, Biasotto M, Brai M, Misiano G, Meo T, Tosi M. Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angiodema. J Hum Genet 1996; 59:308-19.
8. Zuraw BL, Herschbach J. Detection of C1 inhibitor mutations in patients with hereditary angioedema. J Allergy Clin Immunol 2000; 105:541-6.
9. Silverman GA, Bird PI, Carrell RW et al. The serpins are an expanding superfamily of structurally similar but functionally diverse proteins. Evolution, mechanism of inhibition, novel functions and a revised nomenclature. J Biol Chem 2001; 276:33293-6.
10. van Geffen M, Cugno M, Lap P, Loof A, Cicardi M, van Heerde W. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012; 167:472-8.
11. Caccia S, Castelli R, Maiocchi D, Bergamaschini L, Cugno M. Interaction of C1 inhibitor with thrombin on the endothelial surface. Blood Coagul Fibrinolysis 2011; 22:571-5.
12. Landerman NS, Webster ME, Becker EL, Ratcliffe HE. Hereditary angioneurotic edema. Deficiency of inhibitor for serum globulin permeability factor and/or plasma kallikrein. J Allergy 1962; 33:330-41.
13. Schapira M, Silver D, Scott CF et al. Prekallikrein activation and high-molecular-weight kininogen consumption in hereditary angioedema. N Engl J Med 1983; 308:1050-3.
14. Curd JG, Prograis LJ Jr, Cochrane CG. Detection of active kallikrein in induced blister fluids of hereditary angioedema patients. J Exp Med 1980; 152:742-7.
15. Shoemaker LR, Schurman SJ, Donaldson VH, Davis AE III. Hereditary angioneurotic oedema: characterization of plasma kinin and vascular permeability-enhancing activities. Clin Exp Immunol 1994; 95:22-8.
16. Nussberger J, Cugno M, Amstutz C, Cicardi M, Pellacani A, Agostoni A. Plasma bradykinin in angio-oedema. Lancet 1998; 351:1693-7.
17. Cugno M, Hack CE, de Boer JP, Eerenberg AJ, Agostoni A, Cicardi M. Generation of plasmin during acute attacks of hereditary angioedema. J Lab Clin Med 1993; 121:38-43.
18. Kleniewski J, Blankenship DT, Cardin AD, Donaldson VH. Mechanism of enhanced kinin release from high molecular weight kininogen by plasma kallikrein after its exposure to plasmin. J Lab Clin Med 1992; 120:129-39.
19. Cugno M, Cicardi M, Bottasso B et al. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood 1997; 89:3213-8.
20. Agostoni A, Cicardi M. Hereditary and acquired C1-inhibitor deficiency: biological and clinical characteristics in 235 patients. Medicine (Baltimore) 1992; 71:206-15.
21. Zilberberg M, Jacobsen T, Tillotson G. The burden of hospitalizations and emergency department visits with hereditary angioedema and angioedema in the United States 2007. Allergy Asthma Proc 2010; 31:511-9.
22. Lumry WR, Castaldo AJ, Vernon MK, Blaustein MB, Wilson DA, Horn PT. The humanistic burden of hereditary angioedema: impact on health-related quality of life, productivity, and depression. Allergy Asthma Proc 2010; 31:407-14.
23. Bouillet L, Launay D, Fain O et al. Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. Ann Allergy Asthma Immunol 2013; 111:290-4.
24. Cicardi M, Bork K, Caballero T et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147-57.
25. Costantino G, Casazza G, Bossi I et al. Long-term prophylaxis in hereditary angio-oedema: a systematic review. BMJ Open 2012; 2:e000524.
26. Riedl M. Hereditary angioedema therapies in the United States: movement toward an international treatment consensus. Clin Ther 2012; 34:623-30.
27. Agostoni A, Aygoren-Pursun E, Binkley KE et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004; 114(3 Suppl):S51-131.
28. Scott CF, Shull B, Müller-Esterl W, Colman RW. Rapid direct determination of low and high molecular weight kininogen in human plasma by particle concentration fluorescence immunoassay (PCFIA). Thromb Haemost 1997; 77:109-18.
29. Gallimore MJ, Friberger P. Simple chromogenic peptide substrate assays for determining prekallikrein, kallikrein inhibition and kallikrein-"like" activities in human plasma. Thromb Res 1982; 25:293-8.
30. Berrettini M, Lammle B, White T, Curd J, Griffin JH. Detection of the in vivo cleavage of high molecular weight kininogen in human plasma by immunoblotting with monoclonal antibodies. Blood 1986; 68:455-62.
31. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994; 93:870-6.
32. Pappalardo E, Cicardi M, Duponchel C et al. Frequent de novo mutations and exon deletions in the c1inhibitor gene of patients with angioedema. J Allergy Clin Immunol 2000; 106:1147-54.
33. Donaldson VH, Evans RR. A biochemical abnormality in herediatry angioneurotic edema: absence of serum inhibitor of C' 1-esterase. Am J Sci 1963; 31:37-44.
34. Austen KF, Beer F. The measurement of second component of human complement (C'2hu) by its interaction with Eac'1agp, 4gp cells. J Immunol 1964; 92:946-57.
35. Austen KF, Sheffer AL. Detection of hereditary angioneurotic edema by demonstration of a reduction in the second component of human complement. N Engl J Med 1965; 272:649-56.
36. Cullmann W, Kovary PM, Muller N, Dick W. Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE-C1-INH). Clin Exp Immunol 1982; 49:618-22.
37. Donaldson VH, Harrison RA. Complexes between C1-inhibitor, kallikrein, high molecular weight kininogen, plasma thromboplastin antecedent, and plasmin in normal human plasma and hereditary angioneurotic edema plasmas containing dysmorphic C1-inhibitors: role of cold activation. Blood 1982; 60:121-9.
38. Fields T, Ghebrehiwet B, Kaplan AP. Kinin formation in hereditary angioedema plasma: evidence against kinin derivation from C2 and in support of "spontaneous" formation of bradykinin. J Allergy Clin Immunol 1983; 72:54-60.
39. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW. Alpha 2-macroglobulin-kallikrein complexes detect contact system activation in hereditary angioedema and human sepsis. Blood 1991; 77:2660-7.
40. Cugno M, Bergamaschini L, Uziel L et al. Haemostasis contact system and fibrinolysis in hereditary angioedema (C1-inhibitor deficiency). J Clin Chem Clin Biochem 1988; 26:423-7.
41. Cugno M, Cicardi M, Coppola R, Agostoni A. Activation of factor XII and cleavage of high molecular weight kininogen during acute attacks in hereditary and acquired C1-inhibitor deficiencies. Immunopharmacology 1996; 33:361-4.
42. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999; 104:1321-2.
43. Cugno M, Zanichelli A, Bellatorre AG, Griffini S, Cicardi M. Plasma biomarkers of acute attacks in patients with angioedema due to C1-inhibitor deficiency. Allergy 2009; 64:254-7.
44. Joseph K, Tuscano TB, Kaplan AP. Studies of the mechanisms of bradykinin generation in hereditary angioedema plasma. Ann Allergy Asthma Immunol 2008; 101:279-86.
45. Kaplan AP. Enzymatic pathways in the pathogenesis of hereditary angioedema: the role of C1 inhibitor therapy. J Allergy Clin Immunol 2010; 126:918-25.
46. Joseph K, Tholanikunnel TE, Kaplan AP. Treatment of episodes of hereditary angioedema with C1 inhibitor: serial assessment of observed abnormalities of the plasma bradykinin-forming pathway and fibrinolysis. Ann Allergy Asthma Immunol 2010; 104:50-4.
47. Donaldson VH. Mechanisms of activation of C'1 esterase in hereditary angioneurotic edema plasma in vitro. J Exp Med 1968; 127:411-29.
48. Ghebrehiwet B, Randazzo BP, Dunn JT, Silverberg M, Kaplan AP. Mechanisms of activation of the classical pathway of complement by Hageman factor fragment. J Clin Invest 1983; 71:1450-6.
49. Ghebrehiwet B, Silverberg M, Kaplan AP. Activation of the classical pathway of complement by Hageman factor fragment. J Exp Med 1981; 153:665-76.
50. Cugno M, Nuijens J, Hack E et al. Plasma levels of C1-inhibitor complexes and cleaved C1-inhibitor in patients with angioneurotic edema. J Clin Invest 1990; 85:1215-20.
51. Zingale LC, Castelli R, Zanichelli A, Cicardi M. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course and conventional management. Immunol Allergy Clin North Am 2006; 26:669-90.
52. Craig LJ, Levy RJ, Wasserman RL et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801-8.
53. Cicardi M, Banerji A, Bracho F et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-41.
54. Cicardi M, Levy RJ, McNeil DL et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523-31.
55. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its relationships with complement. Mol Immunol 2010; 47:2161-9.
56. Laurell CB, Rannevik G. A comparison of plasma protein changes induced by Danazol, pregnancy and estrogens. J Clin Endocrinol 1979; 49:719-25.
57. Cugno M, Scott CF, Salerno F et al. Parallel reduction of plasma levels of high and low molecular weight kininogen in patients with cirrhosis. Thromb Haemost 1999; 82:1428-32.
58. Defendi F, Charignon D, Ghannam A et al. Enzymatic assays for the diagnosis of Bradykinin-dependent angioedema. PLoS One 2013; 8:e70140.
59. Cicardi M, Zingale L, Zanichelli A, Pappalardo E, Cicardi B. C1 inhibitor: molecular and clinical aspects. Springer Semin Immunopathol 2005; 27:286-98.
60. Rosen FS, Davis AE III. Deficiencies of C1 inhibitor. Best Pract Res Clin Gastroenterol 2005; 19:251-61.
61. Bors A, Csuka D, Varga L et al. Less severe clinical manifestations in patients with hereditary angioedema with missense C1INH gene mutations. J Allergy Clin Immunol 2013; 131:1708-11.